Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR4 | Q13639 | 10/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | HTR3A | P46098 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | GLA | P06280 | 1/20 | 0.87 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29767008 | 1.00 | HTR4 (1.00) | HTR4CYP3A4MEN1ALDH1A1CYP2D6 | |
| Hydrochloric Acid SCHEMBL6836668 | 0.99 | HTR4 (1.00) | HTR4CYP3A4MEN1ALDH1A1CYP2D6 | |
| Hydrochloric Acid SCHEMBL27977233 | 0.98 | HTR4 (0.96) | HTR4CYP3A4MEN1ALDH1A1CYP2D6 | |
| SCHEMBL29386039 | 0.93 | HTR4 (1.00) | HTR4CYP3A4MEN1ALDH1A1CYP2D6 | |
| SCHEMBL2579561 | 0.93 | HTR4 (1.00) | HTR4CYP3A4MEN1ALDH1A1CYP2D6 | |
| Hydrochloric Acid SCHEMBL22532550 | 0.92 | HTR4 (0.98) | HTR4CYP3A4MEN1ALDH1A1CYP2D6 | |
| Hydrochloric Acid SCHEMBL7357853 | 0.83 | HTR4 (0.98) | HTR4CYP3A4MEN1ALDH1A1CYP2D6 | |
| SCHEMBL7351188 | 0.83 | HTR4 (1.00) | HTR4CYP3A4MEN1ALDH1A1CYP2D6 | |
| Hydrochloric Acid SCHEMBL194956 | 0.82 | HTR4 (0.98) | HTR4CYP3A4MEN1ALDH1A1CYP2D6 | |
| Hydrochloric Acid SCHEMBL7354962 | 0.82 | HTR4 (0.98) | HTR4CYP3A4MEN1ALDH1A1CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1385476-B1 | COMPOSITION FOR TREATING SMALL INTESTINAL BACTERIAL OVERGROWTH (SIBO) AND SIBO-RELATED CONDITIONS | CEDARS SINAI MEDICAL CENTER (US) | 2021-01-27 | — | — | EP | disclosed |
| US-10568851-B2 | Compounds and methods of treating ocular disorders | CASE WESTERN RESERVE UNIVERSITY (US) | 2020-02-25 | — | — | US | disclosed |
| US-10426773-B2 | Systems pharmacology for treating ocular disorders | CASE WESTERN UNIVERSITY (US) | 2019-10-01 | — | — | US | disclosed |
| US-20190099420-A1 | SYSTEMS PHARMACOLOGY FOR TREATING OCULAR DISORDERS | CASE WESTERN UNIVERSITY | 2019-04-04 | — | — | US | disclosed |
| US-20180071285-A1 | SYSTEMS PHARMACOLOGY FOR TREATING OCULAR DISORDERS | CASE WESTERN RESERVE UNIVERSITY | 2018-03-15 | — | — | US | disclosed |
| US-20180071285-A1 | SYSTEMS PHARMACOLOGY FOR TREATING OCULAR DISORDERS | CASE WESTERN RESERVE UNIVERSITY | 2018-03-15 | — | — | US | disclosed |
| EP-2305213-B1 | The treatment of small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions | CEDARS SINAI MEDICAL CENTER (US) | 2017-06-28 | — | — | EP | disclosed |
| US-20170095543-A1 | METHODS OF DIAGNOSING AND TREATING SMALL INTESTINAL BACTERIAL OVERGROWTH (SIBO) AND SIBO-RELATED CONDITIONS | CEDARS-SINAI MEDICAL CENTER (US) | 2017-04-06 | — | — | US | disclosed |
| EP-2267445-B1 | Methods of detecting small intestinal bacterial overgrowth (SIBO) in a human subject | CEDARS SINAI MEDICAL CENTER (US) | 2016-08-17 | — | — | EP | disclosed |
| US-9358276-B2 | Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions | CEDARS-SINAI MEDICAL CENTER (US) | 2016-06-07 | — | — | US | disclosed |
| US-20060147496-A1 | Diagnosis of irritable bowel disorders; fibromyalgia; chronic fatique syndrome; antidepressants; tinnitus; autism; autoimmune disease; Crohn's disease; quantitative analysis of serotonine, bile acid in sample | CEDARS-SINAI MEDICAL CENTER (US) | 2006-07-06 | — | — | US | disclosed |
| EP-1385476-A4 | METHODS OF DIAGNOSING AND TREATING SMALL INTESTINAL BACTERIAL OVERGROWTH (SIBO) AND SIBO-RELATED CONDITIONS | CEDARS SINAI MEDICAL CENTER (US) | 2006-06-14 | — | — | EP | disclosed |
| US-7048906-B2 | Calibration; administering antiseptic compound | CEDARS-SINAI MEDICAL CENTER (US) | 2006-05-23 | — | — | US | disclosed |
| US-20050261344-A1 | Treatment of lower urinary tract symptoms associated with overactive bladder in men and women | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-11-24 | — | — | US | disclosed |
| EP-1551394-A1 | TREATMENT OF LOWER URINARY TRACT SYMPTOMS ASSOCIATED WITH OVERACTIVE BLADDER IN MEN AND WOMEN | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-07-13 | — | — | EP | disclosed |
| WO-2004017960-A1 | TREATMENT OF LOWER URINARY TRACT SYMPTOMS ASSOCIATED WITH OVERACTIVE BLADDER IN MEN AND WOMEN | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-03-04 | — | — | WO | disclosed |
| EP-1385476-A2 | METHODS OF DIAGNOSING AND TREATING SMALL INTESTINAL BACTERIAL OVERGROWTH (SIBO) AND SIBO-RELATED CONDITIONS | CEDARS-SINAI MEDICAL CENTER (US) | 2004-02-04 | — | — | EP | disclosed |
| WO-2002083926-A2 | METHODS OF DIAGNOSING AND TREATING SMALL INTESTINAL BACTERIAL OVERGROWTH (SIBO) AND SIBO-RELATED CONDITIONS | CEDARS-SINAI MEDICAL CENTER (US) | 2002-10-24 | — | — | WO | disclosed |
| US-20020039599-A1 | Calibration; administering antiseptic compound | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2002-04-04 | — | — | US | disclosed |
| WO-1995025100-A1 | USE OF 4-AMINO-5-CHLORO-2-METHOXYBENZOIC ESTERS AS 5-HT4 AGONISTS | SANOFI (FR) | 1995-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10426773-B2 | Systems pharmacology for treating ocular disorders | GRK1, MTNR1A, MTNR1B | HTR4 248/4885CYP3A4 1389/4885MEN1 2477/4885 |
| US-20180071285-A1 | SYSTEMS PHARMACOLOGY FOR TREATING OCULAR DISORDERS | GRK1, MTNR1A, MTNR1B | HTR4 248/4885CYP3A4 1389/4885MEN1 2477/4885 |
| US-20190099420-A1 | SYSTEMS PHARMACOLOGY FOR TREATING OCULAR DISORDERS | GRK1, MTNR1A, MTNR1B | HTR4 248/4885CYP3A4 1389/4885MEN1 2477/4885 |
| US-10568851-B2 | Compounds and methods of treating ocular disorders | ALDH1A2, TXNRD2, TXNRD1 | HTR4 2871/4885CYP3A4 4631/4885MEN1 4699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.